Get started
LILLY DRNLILLY DRNLILLY DRN

LILLY DRN

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Seasonals Bonds

LILY34 chart


Full chart

Key facts today


Eli Lilly's lepodisiran showed a 93.9% average reduction in lipoprotein(a) in a Phase 2 study, meeting primary and secondary endpoints, with no serious side effects. Phase 3 study upcoming.
Eli Lilly plans to seek a re-examination of the European Medicines Agency's rejection of its marketing application for Kisunla, an Alzheimer's drug, due to safety concerns.
Isomorphic Labs, part of Alphabet, is partnering with Eli Lilly on AI drug discovery after a $600 million funding round to enhance its AI drug design and testing.
Analyze the impactAnalyze the impact

Key stats


Market capitalization
‪4.50 T‬ BRL
Dividend yield (indicated)
0.51%
Price to earnings Ratio (TTM)
5,032.91
Basic EPS (TTM)
0.03 BRL
Net income (FY)
‪57.09 B‬ BRL
Revenue (FY)
‪242.82 B‬ BRL
Shares float
—
Beta (1Y)
−0.71

About Eli Lilly and Company


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
David A. Ricks
Website
lilly.com
Headquarters
Indianapolis
Founded
1876
ISIN
BRLILYBDR006
FIGI
BBG002QBHFC7
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

LILY34 news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

LILY34 highest yielding bonds


XS238628644
ELI LILLY 21/43
Yield to maturity
7.81%
Maturity date
Sep 14, 2043
US532457BZ0
ELI LILLY 20/60
Yield to maturity
6.98%
Maturity date
Sep 15, 2060
US532457AM0
ELI LILLY 2025
Yield to maturity
6.95%
Maturity date
Jun 1, 2025
US532457BY3
ELI LILLY 20/50
Yield to maturity
6.92%
Maturity date
May 15, 2050
LLYC
ELI LILLY 15/25
Yield to maturity
6.92%
Maturity date
Jun 1, 2025
US532457BU1
ELI LILLY 19/59
Yield to maturity
6.03%
Maturity date
Mar 15, 2059
US532457BT4
ELI LILLY 19/49
Yield to maturity
6.02%
Maturity date
Mar 15, 2049
US532457BS6
ELI LILLY 19/39
Yield to maturity
5.83%
Maturity date
Mar 15, 2039
LLY5547405
Eli Lilly and Company 4.95% 27-FEB-2063
Yield to maturity
5.77%
Maturity date
Feb 27, 2063
LLY4217068
Eli Lilly and Company 3.7% 01-MAR-2045
Yield to maturity
5.74%
Maturity date
Mar 1, 2045
LLY4492882
Eli Lilly and Company 3.95% 15-MAY-2047
Yield to maturity
5.71%
Maturity date
May 15, 2047

See all LILY34 bonds 

Sparks


Curated watchlists where LILY34 is featured.

See all sparks 


Check out other big names from the same industry as LILY34.